An Audience With in 2017

Filter By:

Article Type
Year

  • Sean Harper, Amgen's Chief Scientific Officer, talks about how human genetic data can be used to avoid costly failures, prosecute programmes more effectively and discoverde novodrug targets.

    An Audience With

  • Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.

    An Audience With

  • Nora Volkow, director of the National Institute on Drug Abuse (NIDA), discusses her ambitious aim of halving the time needed to develop non-opioid analgesics and anti-addiction drugs.

    An Audience With

  • Katrine Bosley, CEO of Editas Medicines, discusses the technological tractability of CRISPR, the future of the modality's pipeline and the ethical responsibility of working in this space.

    An Audience With

  • Nigel Blackburn, Director of drug development at CRUK, discusses the charity's changing approach to bolstering the cancer drug pipeline.

    An Audience With

  • Joshua Gordon, Director of the National Institute of Mental Health, discusses the evolving RDoC framework for research into mental illnesses, and the appropriate balance between the funding of basic and clinical research.

    An Audience With

  • Yong-Jun Liu, head of research at Sanofi, discusses his push to refocus the company on internal early-stage drug discovery.

    An Audience With

  • Birgitte Volck, head of rare disease R&D at GlaxoSmithKline, discusses the new era of rare disease drug discovery and development.

    An Audience With

  • Thomas Lynch, Bristol-Myers Squibb's new Chief Scientific Officer, discusses his R&D priorities, genomics diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.

    An Audience With

  • Jay Bradner, President of the Novartis Institutes for BioMedical Research, discusses increased interest in chemical biology and open science at Novartis.

    An Audience With

  • Melinda Richter, head of JLABS at J&J Innovation, celebrates the fifth anniversary of a big pharma experiment with life science incubators.

    An Audience With

  • John Jenkins, former Director of the FDA's Office of New Drugs, discusses approvals standards, breakthrough therapy designation and regulatory science hurdles.

    An Audience With